MTOR and atherosclerosis: Several clinical studies have demonstrated that mTOR inhibitors, including temsirolimus, sirolimus, and rapamycin, can be employed either as standalone treatments or in conjunction with other therapeutic approaches to address atherosclerosis, autoimmune disorders, and various malignancies.